Current diagnostic tools, such as serum alpha-fetoprotein (AFP) levels and imaging modalities including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), suffer from suboptimal sensitivity and specificity, particularly in distinguishing HCC from benign liver conditions like cirrhosis. This evidence concerns the gene AFP and hepatocellular carcinoma.